New and emerging contraceptives: a state-of-the-art review

References

• World Health OrganizationMedical Eligibility Criteria for Contraceptive use3rd edGenevaWorld Health Organization2004
   Google Scholar
• ChangMCDevelopment of the oral contraceptivesAm J Obstet Gynecol19781322217219356615
   PubMed Web of Science ®Google Scholar
• DarrochJESinghSTrends in contraceptive need and use in developing countries in 2003, 2008, and 2012: an analysis of national surveysLancet201338198791756176223683642
   PubMed Web of Science ®Google Scholar
• Millennium Development Goals [webpage on the Internet]United Nations2014 Available from: http://www.un.org/millenniumgoals/Accessed September 15, 2013
   Google Scholar
• TemkinOSoranus’ GynecologyBaltimoreThe Johns Hopkins University Press1991
   Google Scholar
• Population Reference Bureau StaffTransitions in world populationPopul Bull2004591143
   Google Scholar
• WinnerBPeipertJFZhaoQEffectiveness of long-acting reversible contraceptionN Engl J Med2012366211998200722621627
   PubMed Web of Science ®Google Scholar
• MerkatzRBTokayBSitruk-WareRLMethods for female contraception: a model for innovation in drug delivery systemsClin Pharmacol Ther200985555355719295503
   PubMed Web of Science ®Google Scholar
• Hugon-RodinJChabbert-BuffetNBouchardPThe future of women’s contraception: stakes and modalitiesAnn N Y Acad Sci2010120523023920840278
   PubMed Web of Science ®Google Scholar
• ZeunSUddinAZeilerBMorrisonDBlodeHPharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogestEur J Contracept Reprod Health Care200914322123219565420
   PubMed Web of Science ®Google Scholar
• AstedtBJeppssonSLiedholmPClinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiolBr J Obstet Gynaecol1979869732736387069
   PubMedGoogle Scholar
• HoffmannHMooreCKovacsLAlternatives of the replacement of ethinylestradiol by natural 17beta-estradiol in dienogest-containing oral contraceptivesDrugs Today (Barc)199935Suppl C10511312973413
   PubMed Web of Science ®Google Scholar
• KivinenSSaureAEfficacy and tolerability of a combined oral contraceptive containing 17 beta-estradiol and desogestrelEur J Contracept Reprod Health Care19961183
   Google Scholar
• HuberJFoidartJMWuttkeWEfficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenoneEur J Contracept Reprod Health Care200051253410836660
   PubMedGoogle Scholar
• SponaJFeichtingerWKindermannCModulation of ovarian function by an oral contraceptive containing 30 micrograms ethinylestradiol in combination with 2.00 mg dienogestContraception19975631851919347211
   PubMed Web of Science ®Google Scholar
• BannemerschultRHankerJPWünschCFoxPAlbringMBrillKA multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cyclesContraception19975652852909437556
   PubMed Web of Science ®Google Scholar
• EndrikatJJaquesMAMayerhoferMPelissierCMüllerUDüsterbergBA twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and toleranceContraception19955242292358605781
   PubMed Web of Science ®Google Scholar
• PiaggioGvon HertzenHGrimesDAVan LookPFTiming of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility RegulationLancet1999353915472110073517
   PubMed Web of Science ®Google Scholar
• DüsterbergBNishinoYPharmacokinetic and pharmacological features of oestradiol valerateMaturitas1982443153247169965
   PubMed Web of Science ®Google Scholar
• ZeunSLuMUddinAZeilerBMorrisonDBlodeHPharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogestEur J Contracept Reprod Health Care200914322123219565420
   PubMed Web of Science ®Google Scholar
• OettelMBreitbarthHElgerWThe pharmacological profile of dienogestEur J Contracept Reprod Health Care19994Suppl 1213
   Google Scholar
• MueckAOSeegerHBühlingKJWhy use of dienogest for the first contraceptive pill with estradiol?Gynecol Endocrinol201026210911319672744
   PubMed Web of Science ®Google Scholar
• Ben-RafaelZMastroianniLJrMeloniFLeeMSFlickingerGLTotal estradiol, free estradiol, sex hormone-binding globulin, and the fraction of estradiol bound to sex hormone-binding globulin in human follicular fluidJ Clin Endocrinol Metab1986635110611113093520
   PubMed Web of Science ®Google Scholar
• EndrikatJParkeSTrummerDSchmidtWDuijkersIKlippingCOvulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studiesContraception200878321822518692612
   PubMed Web of Science ®Google Scholar
• PalaciosSWildtLParkeSMachlittARömerTBitzerJEfficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trialEur J Obstet Gynecol Reprod Biol20101491576219969409
   PubMed Web of Science ®Google Scholar
• AhrendtHJMakalováDParkeSMellingerUMansourDBleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrelContraception200980543644419835717
   PubMed Web of Science ®Google Scholar
• JungeWMellingerUParkeSSerraniMMetabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre studyClin Drug Investig2011318573584
   PubMed Web of Science ®Google Scholar
• FraserISZeunSMachlittAMellingerUA novel oral contraceptive comprising estradiol valerate/dienogest for the treatment of heavy and/or prolonged menstrual bleeding without organic cause: a double-blind, randomised, placebo-controlled trialInt J Gynecol Obstet2009107Suppl 2S183S184
   Google Scholar
• JensenJMachlittAMellingerUSchaefersMFraserISA multicenter, double-blind, randomized, placebo-controlled study of oral estradiol valerate/dienogest for the treatment of heavy and/or prolonged menstrual bleedingFertil Steril2009923S32
   Google Scholar
• WesthoffCKaunitzAMKorverTEfficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trialObstet Gynecol2012119598999922525910
   PubMed Web of Science ®Google Scholar
• MansourDVerhoevenCSommerWEfficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimenEur J Contracept Reprod Health Care201116643044321995590
   PubMed Web of Science ®Google Scholar
• DingerJAssmannAMöhnerSMinhTDRisk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control studyJ Fam Plann Reprod Health Care201036312312920659364
   PubMedGoogle Scholar
• LidegaardONielsenLHSkovlundCWLøkkegaardEVenous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–2010BMJ2012344e299022577198
   PubMed Web of Science ®Google Scholar
• BitzerJAmyJJBeerthuizenRStatement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolismEur J Contracept Reprod Health Care201318314314723578274
   PubMed Web of Science ®Google Scholar
• Coelingh BenninkHJSkoubySBouchardPHolinkaCFOvulation inhibition by estetrol in an in vivo modelContraception200877318619018279689
   PubMed Web of Science ®Google Scholar
• UrdlWApterDAlpersteinAORTHO EVRA/EVRA 003 Study GroupContraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraceptionEur J Obstet Gynecol Reprod Biol2005121220221016054963
   PubMed Web of Science ®Google Scholar
• AbramsLSSkeeDMNatarajanJWongFAAndersonGDPharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sitesBr J Clin Pharmacol200253214114611851637
   PubMed Web of Science ®Google Scholar
• AbramsLSSkeeDMNatarajanJWongFALasseterKCMultiple-dose pharmacokinetics of a contraceptive patch in healthy women participantsContraception200164528729411777488
   PubMed Web of Science ®Google Scholar
• AbramsLSSkeeDMNatarajanJPharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exerciseJ Clin Pharmacol200141121301130911762557
   PubMed Web of Science ®Google Scholar
• SicatBLOrtho Evra, a new contraceptive patchPharmacotherapy200323447248012680477
   PubMed Web of Science ®Google Scholar
• AudetMCMoreauMKoltunWDORTHO EVRA/EVRA 004 Study GroupEvaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trialJAMA2001285182347235411343482
   PubMed Web of Science ®Google Scholar
• JickSSHagbergKWKayeJAORTHO EVRA and venous thromboembolism: an updateContraception201081545245320399954
   PubMed Web of Science ®Google Scholar
• ZiemanMGuillebaudJWeisbergEShangoldGAFisherACCreasyGWContraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled dataFertil Steril2002772 Suppl 2S13S1811849631
   PubMed Web of Science ®Google Scholar
• FoeghMArcherDFStanczykFZRubinAMishellDROvarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrelContraception201387220121123036478
   PubMed Web of Science ®Google Scholar
• HorneFMBlitheDLProgesterone receptor modulators and the endometrium: changes and consequencesHum Reprod Update200713656758017630398
   PubMed Web of Science ®Google Scholar
• MutterGLBergeronCDeligdischLThe spectrum of endometrial pathology induced by progesterone receptor modulatorsMod Pathol200821559159818246050
   PubMed Web of Science ®Google Scholar
• Watson PharmaceuticalsEfficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception (Simplify) Available from: http://clinicaltrials.gov/show/NCT01140217. NLM identifier: NCT01140217Accessed January 9, 2014
   Google Scholar
• Heger-MahnDWarlimontCFaustmannTGerlingerCKlippingCCombined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteersEur J Contracept Reprod Health Care20049317318115697107
   PubMed Web of Science ®Google Scholar
• JungeWHeger-MahnDTrummerDMerzMInvestigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover studyDrugs R D201313322323324043457
   PubMedGoogle Scholar
• HaukkamaaMLaurikka-RouttiMHeikinheimoOTransdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in salivaContraception19914432692761764943
   PubMed Web of Science ®Google Scholar
• KumarNKoideSSTsongYYSundaramKNestorone: a progestin with a unique pharmacological profileSteroids20006510–1162963611108869
   PubMed Web of Science ®Google Scholar
• Sitruk-WareRSmallMKumarNTsongYYSundaramKJackaniczTNestorone: clinical applications for contraception and HRTSteroids20036810–1390791314667982
   PubMed Web of Science ®Google Scholar
• FraserISWeisbergEKumarNAn initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptiveContraception200776643243818061700
   PubMed Web of Science ®Google Scholar
• Sitruk-WareRNathAMishellDRContraception technology: past, present and futureContraception201387331933022995540
   PubMed Web of Science ®Google Scholar
• BracheVMishellDRLahteenmakiPOvarian function during use of vaginal rings delivering three different doses of NestoroneContraception200163525726111448466
   PubMed Web of Science ®Google Scholar
• GuazzelliCABarreirosFABarbosaRde AraújoFFMoronAFExtended regimens of the vaginal contraceptive ring: cycle controlContraception200980543043519835716
   PubMed Web of Science ®Google Scholar
• BarreirosFAGuazzelliCABarbosaRde AssisFde AraújoFFExtended regimens of the contraceptive vaginal ring: evaluation of clinical aspectsContraception201081322322520159178
   PubMed Web of Science ®Google Scholar
• SzarewskiAHigh acceptability and satisfaction with NuvaRing useEur J Contracept Reprod Health Care20027Suppl 23136 discussion 37–3912659400
   PubMedGoogle Scholar
• AhrendtHJNisandIBastianelliCEfficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenoneContraception200674645145717157101
   PubMed Web of Science ®Google Scholar
• LopezLMGrimesDAGalloMFStocktonLLSchulzKFSkin patch and vaginal ring versus combined oral contraceptives for contraceptionCochrane Database Syst Rev20134CD00355223633314
   PubMed Web of Science ®Google Scholar
• NathASitruk-WareRProgesterone vaginal ring for contraceptive use during lactationContraception201082542843420933116
   PubMed Web of Science ®Google Scholar
• MassaiRMirandaPValdésPPreregistration study on the safety and contraceptive efficacy of the progesterone-releasing vaginal ring in Chilean nursing womenContraception199960191410549447
   PubMed Web of Science ®Google Scholar
• SivinIDíazSCroxattoHBContraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUDContraception19975542252329179454
   PubMed Web of Science ®Google Scholar
• MassaiRQuinterosEReyesMVExtended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trialContraception200572535235716246661
   PubMed Web of Science ®Google Scholar
• Indian Council of Medical ResearchEvaluation of Progesterone vaginal ring v/s Cu T 380 A IUD in lactating women Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3133. CTRI number: CTRI/2011/07/001874Accessed January 9, 2014
   Google Scholar
• BracheVMishellDRLahteenmakiPOvarian function during use of vaginal rings delivering three different doses of NestoroneContraception200163525726111448466
   PubMed Web of Science ®Google Scholar
• BracheVPayánLJFaundesACurrent status of contraceptive vaginal ringsContraception201387326427223040125
   PubMed Web of Science ®Google Scholar
• SivinIMishellDRAlvarezFContraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trialContraception200571212212915707562
   PubMed Web of Science ®Google Scholar
• GilliamMLNeustadtAKozloskiMMistrettaSTilmonSGodfreyEAdherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trialObstet Gynecol2010115350351020177280
   PubMed Web of Science ®Google Scholar
• Sitruk-WareRMerkatzRSussmanHVarianoBA one year contraceptive vaginal ring delivering Nestorone and ethinyl-estradiolProgram and abstracts of the 11th Congress of the European Society of Contraception and Reproductive HealthMay 19–22, 2010The Hague, The Netherlands Abstract SS4–2
   Google Scholar
• MerkatzRSussmanHSivinIPreliminary results from a phase III study of the Nestorone/ethinyl estradiol contraceptive vaginal ring: a new, long acting (one year) user controlled contraceptive methodProgram and abstracts of the 11th Congress of the European Society of Contraception and Reproductive HealthMay 19–22, 2010The Hague, The Netherlands Abstract FC–01
   Google Scholar
• JohanssonEDSitruk-WareRNew delivery systems in contraception: vaginal ringsAm J Obstet Gynecol2004190Suppl 4S54S5915105799
   PubMed Web of Science ®Google Scholar
• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women Available from: http://clinicaltrials.gov/show/NCT01586000. NLM identifier: NCT01586000Accessed January 9, 2014
   Google Scholar
• JensenJTVaginal ring delivery of selective progesterone receptor modulators for contraceptionContraception201387331431823040126
   PubMed Web of Science ®Google Scholar
• Cyclofem® [webpage on the Internet]Khlong Luang DistrictConcept Foundation2009 Available from: http://www.conceptfoundation.org/hormonal-contraception.phpAccessed January 9, 2014
   Google Scholar
• LuukkainenTLevonorgestrel-releasing intrauterine deviceAnn Med199022285902113816
   PubMed Web of Science ®Google Scholar
• LuukkainenTThe levonorgestrel intrauterine system: therapeutic aspectsSteroids20006510–1169970211108879
   PubMed Web of Science ®Google Scholar
• OdlindVLong-term experience of a levonorgestrel-releasing intrauterine systemEur J Contracept Reprod Health Care1996143193239678114
   PubMedGoogle Scholar
• Gemzell-DanielssonKSchellschmidtIApterDA randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and MirenaFertil Steril2012973616622.e122222193
   PubMed Web of Science ®Google Scholar
• BahamondesMVHidalgoMMBahamondesLMonteiroIEase of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidasContraception2011845e11e1622018132
   PubMedGoogle Scholar
• Medicines360A study of levonorgestrel-releasing intrauterine system for long-term, reversible contraception Available from: http://www.clinicaltrials.gov/ct2/show/NCT00995150?term=medicines360&rank=1. NLM identifier: NCT00995150Accessed January 9, 2013
   Google Scholar
• GoodmanALHodgenGDProgesterone receptor antagonistsAdashiEYRockJARosenwaksZReproductive Endocrinology, Surgery, and TechnologyPhiladelphiaLippincott-Raven Publishers1996548558
   Google Scholar
• ElgerWBartleyJSchneiderBKaufmannGSchubertGChwaliszKEndocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activitySteroids20006510–1171372311108882
   PubMed Web of Science ®Google Scholar
• AttardiBJBurgensonJHildSAReelJRBlyeRPCDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent anti-progestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914Mol Cell Endocrinol20021881–211112311911951
   PubMed Web of Science ®Google Scholar
• BlitheDLNiemanLKBlyeRPStrattonPPassaroMDevelopment of the selective progesterone receptor modulator CDB-2914 for clinical indicationsSteroids20036810–131013101714667994
   PubMed Web of Science ®Google Scholar
• GainerEEUlmannAPharmacologic properties of CDB(VA)-2914Steroids20036810–131005101114667993
   PubMed Web of Science ®Google Scholar
• BrennerRMSlaydenODNathATsongYYSitruk-WareRIntrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaquesContraception201081433634220227552
   PubMed Web of Science ®Google Scholar
• ChwaliszKGargRBrennerRSlaydenOWinkelCElgerWRole of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)Reprod Biol Endocrinol20064Suppl 1S817118172
   PubMed Web of Science ®Google Scholar
• MeirikOFraserISd’ArcanguesCWHO Consultation on Implantable Contraceptives for WomenImplantable contraceptives for womenHum Reprod Update200391495912638781
   PubMed Web of Science ®Google Scholar
• MansourDBahamondesLCritchleyHDarneyPFraserISThe management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant usersContraception201183320221021310280
   PubMed Web of Science ®Google Scholar
• LähteenmäkiPWeinerELähteenmäkiPJohanssonELuukkainenTContraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435Contraception198123163757471746
   PubMed Web of Science ®Google Scholar
• DíazSSchiappacasseVPavezMClinical trial with Nestorone subdermal contraceptive implantsContraception199551133387750282
   PubMed Web of Science ®Google Scholar
• SivinICroxattoHBahamondesLTwo-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 womenContraception200469213714414759619
   PubMed Web of Science ®Google Scholar
• International Consortium for Emergency Contraception [homepage on the Internet]New YorkInternational Consortium for Emergency Contraception2014 Available from: http://www.cecinfo.org/Accessed January 22, 2013
   Google Scholar
• TrussellJRodríguezGEllertsonCNew estimates of the effectiveness of the Yuzpe regimen of emergency contraceptionContraception19985763633699693395
   PubMed Web of Science ®Google Scholar
• Task Force on Postovulatory Methods of Fertility RegulationRandomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraceptionLancet199835291264284339708750
   PubMed Web of Science ®Google Scholar
• von HertzenHPiaggioGVan LookPFEmergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility RegulationLancet1998352914419399863822
   PubMed Web of Science ®Google Scholar
• WuSGodfreyEMWojdylaDCopper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trialBJOG2010117101205121020618314
   PubMed Web of Science ®Google Scholar
• CreininMDSchlaffWArcherDFProgesterone receptor modulator for emergency contraception: a randomized controlled trialObstet Gynecol200610851089109717077229
   PubMed Web of Science ®Google Scholar
• GlasierAFCameronSTFinePMUlipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysisLancet2010375971455556220116841
   PubMed Web of Science ®Google Scholar
• FinePMathéHGindeSCullinsVMorfesisJGainerEUlipristal acetate taken 48–120 hours after intercourse for emergency contraceptionObstet Gynecol20101152 Pt 125726320093897
   PubMed Web of Science ®Google Scholar
• BracheVCochonLDeniaudMCroxattoHBUlipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimensContraception201388561161823809278
   PubMed Web of Science ®Google Scholar
• PallMFridénBEBrännströmMInduction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind studyHum Reprod20011671323132811425807
   PubMed Web of Science ®Google Scholar
• BataMSAl-RamahiMSalhabASGharaibehMNSchwartzJDelay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover studyJ Clin Pharmacol200646892593216855077
   PubMed Web of Science ®Google Scholar
• RichardsJSPerspective: the ovarian follicle – a perspective in 2001Endocrinology200114262184219311356661
   PubMed Web of Science ®Google Scholar
• JesamCSalvatierraAMSchwartzJLCroxattoHBSuppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraceptionHum Reprod201025236837319933235
   PubMed Web of Science ®Google Scholar
• EdelmanABJensenJTHenneboldJDA nonhormonal model for emergency contraception: prostaglandin synthesis inhibitor effects on luteal function and lifespan, a pilot studyContraception201081649650020472116
   PubMed Web of Science ®Google Scholar
• EdelmanABJensenJTDoomCHenneboldJDImpact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in womenContraception201387335235722902348
   PubMed Web of Science ®Google Scholar
• Pearce-PrattRPhillipsDMSulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1Biol Reprod19965411731828838015
   PubMed Web of Science ®Google Scholar
• Sitruk-WareRBracheVMaguireRPharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for “dual protection” contraceptionContraception200775645446017519152
   PubMed Web of Science ®Google Scholar
• EliasCJCogginsCAlvarezFColposcopic evaluation of a vaginal gel formulation of iota-carrageenanContraception19975663873899494773
   PubMed Web of Science ®Google Scholar
• CogginsCBlanchardKAlvarezFPreliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicideSex Transm Infect200076648048311221133
   PubMed Web of Science ®Google Scholar
• VictorAJohanssonEDPlasma levels of d-norgestrel and ovarian function in women using intravaginal rings impregnated with dl-norgestrel for several cyclesContraception1976142215226949897
   PubMed Web of Science ®Google Scholar
• BracheVCroxattoHSitruk-WareREffect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for “dual protection” emergency contraceptionContraception200776211111617656180
   PubMed Web of Science ®Google Scholar
• BracheVCroxattoHKumarNEffect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic studyContraception200979215015419135574
   PubMed Web of Science ®Google Scholar
• TaylorDJLendvayAHalpernVA single-arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrelContraception Epub11262013
   Web of Science ®Google Scholar
• WoolcockJGCritchleyHOMunroMGBroderMSFraserISReview of the confusion in current and historical terminology and definitions for disturbances of menstrual bleedingFertil Steril20089062269228018258230
   PubMed Web of Science ®Google Scholar
• GrimesDASchulzKFRaymondEGSurrogate end points in women’s health research: science, protoscience, and pseudoscienceFertil Steril20109361731173420153470
   PubMed Web of Science ®Google Scholar
• SantelliJRochatRHatfield-TimajchyKUnintended Pregnancy Working GroupThe measurement and meaning of unintended pregnancyPerspect Sex Reprod Health20033529410112729139
   PubMed Web of Science ®Google Scholar
• GipsonJDKoenigMAHindinMJThe effects of unintended pregnancy on infant, child, and parental health: a review of the literatureStud Fam Plann2008391183818540521
   PubMed Web of Science ®Google Scholar
• SedghGSinghSShahIHAhmanEHenshawSKBankoleAInduced abortion: incidence and trends worldwide from 1995 to 2008Lancet2012379981662563222264435
   PubMed Web of Science ®Google Scholar
• World Health OrganizationUnsafe Abortion: Global and Regional Estimates of the Incidence of Unsafe Abortion and Associated Mortality in 20086th edGenevaWorld Health Organization2011 Available from: http://whqlibdoc.who.int/publications/2011/9789241501118_eng.pdfAccessed August 25, 2013
   Google Scholar